利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

85 条记录 (耗时 0.021 秒)

    SIGNALLING SYSTEM
    3.
    发明申请
    SIGNALLING SYSTEM 有权

    公开(公告)号：US20210032332A1

    公开(公告)日：2021-02-04

    申请号：US16848717

    申请日：2020-04-14

    申请人： UCL BUSINESS LTD

    发明人： Martin Pulé ,  Shaun Cordoba ,  Khai Kong

    IPC分类号： C07K16/28 ,  A61K35/17 ,  C07K14/725 ,  C12N5/0783 ,  A61K31/65 ,  C07K14/73

    摘要： The present invention provides a chimeric antigen receptor (CAR) signalling system comprising; (i) a receptor component comprising an antigen binding domain, a transmembrane domain and a first binding domain; and (ii) an intracellular signalling component comprising a signalling domain and a second binding domain which specifically binds the first binding domain of the receptor component; wherein, binding of the first and second binding domains is disrupted by the presence of an agent, such that in the absence of the agent the receptor component and the signalling component heterodimerize and binding of the antigen binding domain to antigen results in signalling through the signalling domain, whereas in the presence of the agent the receptor component and the signalling component do not heterodimerize and binding of the antigen binding domain to antigen does not result in signalling through the signalling domain.

    CELL
    7.
    发明申请
    CELL 有权

    公开(公告)号：US20230113183A1

    公开(公告)日：2023-04-13

    申请号：US17915637

    申请日：2021-04-08

    申请人： AUTOLUS LIMITED

    发明人： Callum McKenzie ,  Shaun Cordoba ,  MArtin Pulé

    IPC分类号： C12N5/0783 ,  C07K14/705 ,  C07K14/725 ,  C12N15/63

    摘要： The present invention relates to a cell which comprises; (a) a chimeric antigen receptor (CAR) or a transgenic T-cell receptor (TCR); and (b) a FasL-binding receptor (FLBR) comprising; (i) a Fas ectodomain and a TNFR endodomain, wherein the TNFR endodomain comprises the signalling portion of the decoy receptor 2 (DcR2), GITR, CD30, XEDAR, CD40, CD27, BCMA or Fn14 endodomain, or (ii) a membrane-bound decoy receptor 3 (DcR3).

    Engineered Cytolytic Immunecell
    8.
    发明申请
    Engineered Cytolytic Immunecell 有权

    公开(公告)号：US20230090553A1

    公开(公告)日：2023-03-23

    申请号：US17823003

    申请日：2022-08-29

    申请人： AUTOLUS LIMITED

    发明人： Shaun Cordoba ,  Shimobi Onuoha ,  Alexander Kinna ,  Simon Thomas ,  Ram Jha ,  Martin Pulé

    IPC分类号： C12N15/85 ,  A61K35/17 ,  C07K14/725 ,  C12N5/0783 ,  G01N33/50

    摘要： The present invention relates to engineered a cytolytic immune cell comprising: i) a releasable protein which comprises a polypeptide of interest (POI) and a first interaction domain; and ii) a retention protein which is retained within an intracellular compartment of the cell and comprises a second interaction domain which binds to the first protein interaction domain, wherein binding between the first protein interaction domain and second protein interaction domain is disrupted by the presence of an agent, such that in the absence of the agent, the first protein interaction domain and second protein interaction domain bind and result in retention of the POI within an intracellular compartment; whereas in the presence of the agent, the first protein interaction domain and second protein interaction do not bind and the POI is released from the intracellular compartment and expressed at the cell surface or secreted by the cell.

    Nucleic acid construct
    9.
    发明授权
    Nucleic acid construct 有权

    公开(公告)号：US11530420B2

    公开(公告)日：2022-12-20

    申请号：US15568859

    申请日：2016-04-26

    申请人： AUTOLUS LIMITED

    发明人： Martin Pulé ,  Shaun Cordoba

    IPC分类号： C12N15/00 ,  C12N15/86 ,  C07K14/705 ,  C07K16/28 ,  C12N15/85

    摘要： The present invention provides a nucleic acid construct comprising the following structure: A-X-B in which A and B are nucleic acid sequences encoding a first and a second polypeptide of interest (POI); and X is a nucleic acid sequence which encodes a cleavage site, wherein either the first or second POI is a transmembrane protein which comprises an intracellular retention signal.